M F Yuen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M F Yuen

Showing results (101-110 of 121) with videos related to

Pageof 13

Sort By:

Gut|May 8, 2007

Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levelsM-F Yuen, Y Tanaka, N Shinkai, et al.

Alimentary Pharmacology & Therapeutics|September 20, 2007

Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infectionY K Yee, T K Cheung, K-M Chu, et al.

Journal of Nanoscience and Nanotechnology|August 22, 2012

Construction and evaluation of high-quality n-ZnO nanorod/p-diamond heterojunctionsC D Wang, S K Jha, Z H Chen, et al.

Alimentary Pharmacology & Therapeutics|August 11, 2005

Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong KongB Xia, H H X Xia, C W Ma, et al.

Alimentary Pharmacology & Therapeutics|September 9, 2004

Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycinQ Gu, H H-X Xia, W H Wang, et al.

Alimentary Pharmacology & Therapeutics|March 8, 2003

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infectionW M Wong, Q Gu, S K Lam, et al.

Alimentary Pharmacology & Therapeutics|November 28, 2002

Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the diseaseW-M Wong, S K Lam, W M Hui, et al.

Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|October 16, 2024

Protein induced by vitamin K absence-II for the surveillance and monitoring of hepatocellular carcinoma in Hong KongR N S Lui, L L Y Mak, K N Kung, et al.

Alimentary Pharmacology & Therapeutics|February 24, 2001

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistanceB C Wong, W M Wong, W H Wang, et al.

Digestion|June 22, 2006

Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapyQ Gu, H H X Xia, J D Wang, et al.

Pageof 13

Search research articles

Showing results (101-110 of 121) with videos related to

Sort By:

Pageof 13

Gut|May 8, 2007

Alimentary Pharmacology & Therapeutics|September 20, 2007

Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infectionY K Yee, T K Cheung, K-M Chu, et al.

Journal of Nanoscience and Nanotechnology|August 22, 2012

Construction and evaluation of high-quality n-ZnO nanorod/p-diamond heterojunctionsC D Wang, S K Jha, Z H Chen, et al.

Alimentary Pharmacology & Therapeutics|August 11, 2005

Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong KongB Xia, H H X Xia, C W Ma, et al.

Alimentary Pharmacology & Therapeutics|September 9, 2004

Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycinQ Gu, H H-X Xia, W H Wang, et al.

Alimentary Pharmacology & Therapeutics|March 8, 2003

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infectionW M Wong, Q Gu, S K Lam, et al.

Alimentary Pharmacology & Therapeutics|November 28, 2002

Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the diseaseW-M Wong, S K Lam, W M Hui, et al.

Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|October 16, 2024

Protein induced by vitamin K absence-II for the surveillance and monitoring of hepatocellular carcinoma in Hong KongR N S Lui, L L Y Mak, K N Kung, et al.

Alimentary Pharmacology & Therapeutics|February 24, 2001

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistanceB C Wong, W M Wong, W H Wang, et al.

Digestion|June 22, 2006

Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapyQ Gu, H H X Xia, J D Wang, et al.

Pageof 13